This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, J. Articles by Ittmann, M. Search for Related Content PubMed PubMed Citation Articles by Wang, J. Articles by Ittmann, M.

Expression of Variant TMPRSS2/ERG Fusion Messenger RNAs Is Associated with Aggressive Prostate Cancer

Department of Pathology, Baylor College of Medicine and Michael E. DeBakey Department of Veterans Affairs Medical Center, Houston, Texas

Requests for reprints: Michael Ittmann, Department of Pathology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030. Phone: 713-798-6196; Fax: 713-798-5838; E-mail: mittmann{at}bcm.tmc.edu.

Recent studies have reported that the majority of prostate cancers express fusion genes in which the 5' region of the androgen-regulated TMPRSS2 gene is fused to an ETS family transcription factor, most commonly the ERG gene. We have characterized in detail the expression of TMPRSS2/ERG fusion mRNAs and correlated the isoforms expressed and expression levels with clinical outcome in cancers from men undergoing radical prostatectomy. Overall, 59% of clinically localized prostate cancers express the TMPRSS2/ERG fusion gene, confirming the initial observations of high frequency expression of this fusion mRNA in prostate cancer. There was significant variation in the alternatively spliced isoforms expressed in different cancers. Expression of an isoform, in which the native ATG in exon 2 of the TMPRSS2 gene is in frame with exon 4 of the ERG gene, was associated with clinical and pathologic variables of aggressive disease. Expression of other isoforms, in which the native ERG ATG in exon 3 was the first in-frame ATG, was associated with seminal vesicle invasion, which is correlated with poor outcome following radical prostatectomy. Cancers not expressing these isoforms tended to express higher levels of fusion mRNAs, and in this group, higher expression levels of fusion mRNA were present in cancers with early prostate-specific antigen recurrence. Thus, both the isoforms of TMPRSS2/ERG fusions expressed and expression level may affect prostate cancer progression. (Cancer Res 2006; 66(17): 8347-51)

This article has been cited by other articles:

				K. H. Metzeler, A. Dufour, T. Benthaus, M. Hummel, M.-C. Sauerland, A. Heinecke, W. E. Berdel, T. Buchner, B. Wormann, U. Mansmann, et al. ERG Expression Is an Independent Prognostic Factor and Allows Refined Risk Stratification in Cytogenetically Normal Acute Myeloid Leukemia: A Comprehensive Analysis of ERG, MN1, and BAALC Transcript Levels Using Oligonucleotide Microarrays J. Clin. Oncol., October 20, 2009; 27(30): 5031 - 5038. [Abstract] [Full Text] [PDF]

				K. G. Hermans, J. L. Boormans, D. Gasi, G. J.H.L. van Leenders, G. Jenster, P. C.M.S. Verhagen, and J. Trapman Overexpression of Prostate-Specific TMPRSS2(exon 0)-ERG Fusion Transcripts Corresponds with Favorable Prognosis of Prostate Cancer Clin. Cancer Res., October 15, 2009; 15(20): 6398 - 6403. [Abstract] [Full Text] [PDF]

				F McCarthy, A Fletcher, N Dennis, C Cummings, H O'Donnell, J Clark, P Flohr, R Vergis, S Jhavar, C Parker, et al. An improved method for constructing tissue microarrays from prostate needle biopsy specimens J. Clin. Pathol., August 1, 2009; 62(8): 694 - 698. [Abstract] [Full Text] [PDF]

				C. Cai, H. Wang, Y. Xu, S. Chen, and S. P. Balk Reactivation of Androgen Receptor-Regulated TMPRSS2:ERG Gene Expression in Castration-Resistant Prostate Cancer Cancer Res., August 1, 2009; 69(15): 6027 - 6032. [Abstract] [Full Text] [PDF]

				J.-M. Mosquera, R. Mehra, M. M. Regan, S. Perner, E. M. Genega, G. Bueti, R. B. Shah, S. Gaston, S. A. Tomlins, J. T. Wei, et al. Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States Clin. Cancer Res., July 15, 2009; 15(14): 4706 - 4711. [Abstract] [Full Text] [PDF]

				A. Gopalan, M. A. Leversha, J. M. Satagopan, Q. Zhou, H. A. Al-Ahmadie, S. W. Fine, J. A. Eastham, P. T. Scardino, H. I. Scher, S. K. Tickoo, et al. TMPRSS2-ERG Gene Fusion Is Not Associated with Outcome in Patients Treated by Prostatectomy Cancer Res., February 15, 2009; 69(4): 1400 - 1406. [Abstract] [Full Text] [PDF]

				M. D. Hofer, R. Kuefer, C. Maier, K. Herkommer, S. Perner, F. Demichelis, T. Paiss, W. Vogel, M. A. Rubin, and J. Hoegel Genome-Wide Linkage Analysis of TMPRSS2-ERG Fusion in Familial Prostate Cancer Cancer Res., January 15, 2009; 69(2): 640 - 646. [Abstract] [Full Text] [PDF]

				R. Snoek, H. Cheng, K. Margiotti, L. A. Wafa, C. A. Wong, E. C. Wong, L. Fazli, C. C. Nelson, M. E. Gleave, and P. S. Rennie In vivo Knockdown of the Androgen Receptor Results in Growth Inhibition and Regression of Well-Established, Castration-Resistant Prostate Tumors Clin. Cancer Res., January 1, 2009; 15(1): 39 - 47. [Abstract] [Full Text] [PDF]

				J. P. Clark, K. W. Munson, J. W. Gu, K. Lamparska-Kupsik, K. G. Chan, J. S. Yoshida, M. H. Kawachi, L. E. Crocitto, T. G. Wilson, Z. Feng, et al. Performance of a Single Assay for Both Type III and Type VI TMPRSS2:ERG Fusions in Noninvasive Prediction of Prostate Biopsy Outcome Clin. Chem., December 1, 2008; 54(12): 2007 - 2017. [Abstract] [Full Text] [PDF]

				Q. Lu, E. Nunez, C. Lin, K. Christensen, T. Downs, D. A. Carson, J. Wang-Rodriguez, and Y.-T. Liu A sensitive array-based assay for identifying multiple TMPRSS2:ERG fusion gene variants Nucleic Acids Res., November 1, 2008; 36(20): e130 - e130. [Abstract] [Full Text] [PDF]

				J. Wang, Y. Cai, W. Yu, C. Ren, D. M. Spencer, and M. Ittmann Pleiotropic Biological Activities of Alternatively Spliced TMPRSS2/ERG Fusion Gene Transcripts Cancer Res., October 15, 2008; 68(20): 8516 - 8524. [Abstract] [Full Text] [PDF]

				K. G. Hermans, H. A. van der Korput, R. van Marion, D. J. van de Wijngaart, A. Ziel-van der Made, N. F. Dits, J. L. Boormans, T. H. van der Kwast, H. van Dekken, C. H. Bangma, et al. Truncated ETV1, Fused to Novel Tissue-Specific Genes, and Full-Length ETV1 in Prostate Cancer Cancer Res., September 15, 2008; 68(18): 7541 - 7549. [Abstract] [Full Text] [PDF]

				Y. Hu, A. Dobi, T. Sreenath, C. Cook, A. Y. Tadase, L. Ravindranath, J. Cullen, B. Furusato, Y. Chen, R. L. Thangapazham, et al. Delineation of TMPRSS2-ERG Splice Variants in Prostate Cancer Clin. Cancer Res., August 1, 2008; 14(15): 4719 - 4725. [Abstract] [Full Text] [PDF]

				G Attard, J E Ang, D Olmos, and J S de Bono Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development J. Clin. Pathol., August 1, 2008; 61(8): 891 - 896. [Abstract] [Full Text] [PDF]

				J.-M. Mosquera, S. Perner, E. M. Genega, M. Sanda, M. D. Hofer, K. D. Mertz, P. L. Paris, J. Simko, T. A. Bismar, G. Ayala, et al. Characterization of TMPRSS2-ERG Fusion High-Grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications Clin. Cancer Res., June 1, 2008; 14(11): 3380 - 3385. [Abstract] [Full Text] [PDF]

				O. R. Saramaki, A. E. Harjula, P. M. Martikainen, R. L. Vessella, T. L.J. Tammela, and T. Visakorpi TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis Clin. Cancer Res., June 1, 2008; 14(11): 3395 - 3400. [Abstract] [Full Text] [PDF]

				R. Mehra, S. A. Tomlins, J. Yu, X. Cao, L. Wang, A. Menon, M. A. Rubin, K. J. Pienta, R. B. Shah, and A. M. Chinnaiyan Characterization of TMPRSS2-ETS Gene Aberrations in Androgen-Independent Metastatic Prostate Cancer Cancer Res., May 15, 2008; 68(10): 3584 - 3590. [Abstract] [Full Text] [PDF]

				M. Mimeault, P. P. Mehta, R. Hauke, and S. K. Batra Functions of Normal and Malignant Prostatic Stem/Progenitor Cells in Tissue Regeneration and Cancer Progression and Novel Targeting Therapies Endocr. Rev., April 1, 2008; 29(2): 234 - 252. [Abstract] [Full Text] [PDF]

				F. Kosari, J. M. A. Munz, C. D. Savci-Heijink, C. Spiro, E. W. Klee, D. M. Kube, L. Tillmans, J. Slezak, R. J. Karnes, J. C. Cheville, et al. Identification of Prognostic Biomarkers for Prostate Cancer Clin. Cancer Res., March 15, 2008; 14(6): 1734 - 1743. [Abstract] [Full Text] [PDF]

				B. E. Helgeson, S. A. Tomlins, N. Shah, B. Laxman, Q. Cao, J. R. Prensner, X. Cao, N. Singla, J. E. Montie, S. Varambally, et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 Gene Fusions in Prostate Cancer Cancer Res., January 1, 2008; 68(1): 73 - 80. [Abstract] [Full Text] [PDF]

				S. Jhavar, A. Reid, J. Clark, Z. Kote-Jarai, T. Christmas, A. Thompson, C. Woodhouse, C. Ogden, C. Fisher, C. Corbishley, et al. Detection of TMPRSS2-ERG Translocations in Human Prostate Cancer by Expression Profiling Using GeneChip Human Exon 1.0 ST Arrays J. Mol. Diagn., January 1, 2008; 10(1): 50 - 57. [Abstract] [Full Text] [PDF]

				A. B Rajput, M. A Miller, A. De Luca, N. Boyd, S. Leung, A. Hurtado-Coll, L. Fazli, E. C Jones, J. B Palmer, M. E Gleave, et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers J. Clin. Pathol., November 1, 2007; 60(11): 1238 - 1243. [Abstract] [Full Text] [PDF]

				J. Lapointe, C. Li, C. P. Giacomini, K. Salari, S. Huang, P. Wang, M. Ferrari, T. Hernandez-Boussard, J. D. Brooks, and J. R. Pollack Genomic Profiling Reveals Alternative Genetic Pathways of Prostate Tumorigenesis Cancer Res., September 15, 2007; 67(18): 8504 - 8510. [Abstract] [Full Text] [PDF]

				R. Mehra, B. Han, S. A. Tomlins, L. Wang, A. Menon, M. J. Wasco, R. Shen, J. E. Montie, A. M. Chinnaiyan, and R. B. Shah Heterogeneity of TMPRSS2 Gene Rearrangements in Multifocal Prostate Adenocarcinoma: Molecular Evidence for an Independent Group of Diseases Cancer Res., September 1, 2007; 67(17): 7991 - 7995. [Abstract] [Full Text] [PDF]

				D. Hessels, F. P. Smit, G. W. Verhaegh, J. A. Witjes, E. B. Cornel, and J. A. Schalken Detection of TMPRSS2-ERG Fusion Transcripts and Prostate Cancer Antigen 3 in Urinary Sediments May Improve Diagnosis of Prostate Cancer Clin. Cancer Res., September 1, 2007; 13(17): 5103 - 5108. [Abstract] [Full Text] [PDF]

				G. Marcucci, K. Maharry, S. P. Whitman, T. Vukosavljevic, P. Paschka, C. Langer, K. Mrozek, C. D. Baldus, A. J. Carroll, B. L. Powell, et al. High Expression Levels of the ETS-Related Gene, ERG, Predict Adverse Outcome and Improve Molecular Risk-Based Classification of Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study J. Clin. Oncol., August 1, 2007; 25(22): 3337 - 3343. [Abstract] [Full Text] [PDF]